United Statesguggenheimpartners.com
None yet. When a new project in the record names Guggenheim Securities, LLC as owner, partner or investor, it shows here.
FB102 shows Phase 1b proof in vitiligo and celiac; Phase 2 in celiac expected H2 2026. Acquisition executed as $77/share cash tender offer; close targeted Q3 2026.
